Evidence map›Paper›PMID 41942137›Full record

Trial reportPediatrics2026

Clinician Perceptions of the Impact of Switching HPV Vaccine Initiation to 9-10 Years.

Peter G Szilagyi, Dennis Gurfinkel, Emma Clark, Christina Albertin, Alison Saville, Sean T O'Leary, Brenda Beaty, Sitaram Vangala, Heide Woo, Charles Golden and 2 more

Abstract readRandomized Controlled TrialPragmatic Clinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Peter G SzilagyiDepartment of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Dennis GurfinkelDepartment of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Emma ClarkDepartment of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Christina AlbertinDepartment of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Alison SavilleDepartment of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Sean T O'LearyAdult and Child Center for Outcomes Research and Delivery Science, University of Colorado and Children's Hospital Colorado, Aurora, Colorado.
Brenda BeatyDepartment of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Sitaram VangalaDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Heide WooDepartment of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Charles GoldenDepartment of Pediatrics, University of California, Irvine, California.
Jasjit SinghDepartment of Pediatrics, University of California, Irvine, California.
Allison KempeAdult and Child Center for Outcomes Research and Delivery Science, University of Colorado and Children's Hospital Colorado, Aurora, Colorado.

Funding

The HPV9-10 Trial: Early Initiation of HPV VaccinationR01CA240649 · NCI · UNIVERSITY OF COLORADO DENVER · PI KEMPE, ALLISON, SZILAGYI, PETER G · 2020 to 2024
$3.2M
NCI NIH HHS R01 CA240649
6 · The paper itself

Abstract

BACKGROUND AND

objectivesAlthough HPV vaccine initiation as early as aged 9 years has been recommended, most clinicians initiate at ages 11 to 12 years. We assessed clinician-reported impact of early initiation on parental responses and vaccine discussions.

methodsAs part of an ongoing cluster randomized pragmatic trial across 31 Colorado and California pediatric practices, we allocated practices to switch HPV vaccine initiation to ages 9 to 10 years or to enhanced usual care (initiation at ages 11 to 12 years). All clinicians received online training on improving HPV vaccination; intervention arm clinicians also received training on initiating at ages 9 to 10 years. We surveyed all clinicians in both arms at 1, 6, 12, 18, 24, 30, and 36 months (all >80% response rates), and queried clinicians in the ages 9 to 10 years arm about vaccination at ages 9 to 10 vs 11 to 12 years.

resultsAlmost all intervention arm clinicians switched rapidly to the ages 9 to 10 years initiation; most control clinicians remained at ages 11 to 12 years. Parental concerns/questions, pushback, hesitancy, and adherence to recommendations did not differ significantly between study arms and were similar at ages 9 to 10 vs 11 to 12 years among intervention arm clinicians. Only about one-tenth of clinicians in both arms brought up sexual activity during HPV vaccine discussions; two-thirds in both arms indicated parents sometimes/often did. Intervention arm clinicians were more likely than controls to state discussions were shorter by a lot/little (55% vs 37%, P = .005) since study initiation.

conclusionsInitiating HPV vaccination at ages 9 to 10 years instead of ages 11 to 12 years had little impact on parental questions/concerns, pushback, hesitancy, or clinicians' ability to convince hesitant parents. Initiation at ages 9 to 10 years was perceived by clinicians to shorten HPV vaccine discussions.

Indexed as

Attitude of Health PersonnelPapillomavirus InfectionsPapillomavirus VaccinesVaccinationCaliforniaChildColoradoHumansParentsPapillomavirus Vaccines

Identifiers

PMID41942137
PMCPMC13641248

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.